# A Randomized Study to Determine the Efficacy of a Taxane and Bevacizumab With or Without Capecitabine as First Line Chemotherapy in Patients With Metastatic Breast Cancer

> **NCT01200212** · PHASE3 · TERMINATED · sponsor: **GBG Forschungs GmbH** · enrollment: 432 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Taxane, Avastin
- **DRUG:** Taxane, Avastin, Xeloda

## Key facts

- **NCT ID:** NCT01200212
- **Lead sponsor:** GBG Forschungs GmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-07
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 432 (ESTIMATED)
- **Why stopped:** A planed interim analysis shows no benefits, but higher adverse event rates for the experimental arm.
- **Last updated:** 2013-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01200212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01200212, "A Randomized Study to Determine the Efficacy of a Taxane and Bevacizumab With or Without Capecitabine as First Line Chemotherapy in Patients With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01200212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*